D
Darryl Toth
Researcher at Baylor University Medical Center
Publications - 29
Citations - 2954
Darryl Toth is an academic researcher from Baylor University Medical Center. The author has contributed to research in topics: Psoriasis & Psoriasis Area and Severity Index. The author has an hindex of 15, co-authored 24 publications receiving 2454 citations.
Papers
More filters
Journal ArticleDOI
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl,Bruce Strober,Alan Menter,Kenneth B. Gordon,Jolanta Weglowska,Lluís Puig,Kim A. Papp,Lynda Spelman,Darryl Toth,Francisco A. Kerdel,April W. Armstrong,Georg Stingl,Alexa B. Kimball,Hervé Bachelez,Jashin J. Wu,Jeffrey J. Crowley,Richard G. Langley,Tomasz Blicharski,Carle Paul,Jean-Philippe Lacour,Stephen K. Tyring,Leon H Kircik,Sergio Chimenti,Kristina Callis Duffin,Jerry Bagel,John Koo,Gary Aras,Joanne Li,Wenjie Song,Cassandra E Milmont,Yifei Shi,Ngozi Erondu,Paul Klekotka,Brian L Kotzin,Ajay Nirula +34 more
TL;DR: Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
Journal ArticleDOI
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
Mark Lebwohl,Stephen K. Tyring,Tiffani K. Hamilton,Darryl Toth,Scott Glazer,Naji H. Tawfik,Patricia A. Walicke,Wolfgang Dummer,Xiaolin Wang,Marvin Garovoy,David M. Pariser +10 more
TL;DR: Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease, and extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses.
Journal ArticleDOI
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon,Richard G. Langley,Craig L. Leonardi,Darryl Toth,M. Alan Menter,Sewon Kang,Michael P. Heffernan,Bruce E. Miller,Regina Hamlin,Liberata Lim,Jianhua Zhong,Rebecca S. Hoffman,Martin M. Okun +12 more
TL;DR: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks and was insufficiently powered to detect rare adverse events associated with adalimumAB.
Journal ArticleDOI
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†
Kim A. Papp,Kristian Reich,Carle Paul,Andrew Blauvelt,W. Baran,Chantal Bolduc,Darryl Toth,Richard G. Langley,J. Cather,Alice B. Gottlieb,Diamant Thaçi,James G. Krueger,Chris B. Russell,Cassandra E Milmont,Joanne Li,Paul Klekotka,Gregory Kricorian,Ajay Nirula +17 more
TL;DR: The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis and is associated with atypical immune responses and central nervous system disorders.
Journal ArticleDOI
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz,Craig L. Leonardi,Giampiero Girolomoni,Darryl Toth,Akimichi Morita,Shyamal A. Balki,Jacek C Szepietowski,Pascaline Regnault,Helen Thurston,Charis Papavassilis +9 more
TL;DR: In this article, the authors compared a retreatment-as-needed versus a fixed-interval regimen for plaque psoriasis in adults with moderate to severe plaque Psoriasis.